Literature DB >> 22126575

MTHFR gene polymorphisms in bladder cancer in the Turkish population.

Muzeyyen Izmirli1, Nihal Inandiklioglu, Deniz Abat, Davut Alptekin, Osman Demirhan, Zuhtu Tansug, Yildirim Bayazit.   

Abstract

Bladder cancer is the 9th most common cancer and is responsible for malignancy related death all on the world. Folate and folate related enzyme polymorphisms related to the cancer risk. The methylene tethrahydrofolate reductase (MTHFR) enzyme is folate related and association of bladder cancer and MTHFR gene. Our purpose was to assess the prevalence of MTHFR gene 677 CT and 1298 AC polymorphisms and Bladder cancer in Turkey. We intended that bladder cancer patients and controls and we used the Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphism (RFLP) methods. The MTHFR gene C677T and A1298C polymorphisms were associated with an increased risk of bladder cancer in our population (For the MTHFR gene C677T polymorphism and A1298C polymorphism; p=0.036<0.05; p=0.278>0.05 respectively). Consequently, the MTHFR gene C677T polymorphism augments the risk of bladder cancer in Turkey.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22126575

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

Review 1.  Association between MTHFR Ala222Val (rs1801133) polymorphism and bladder cancer susceptibility: a systematic review and meta-analysis.

Authors:  Kai Li; Yong ping Hu; Zecheng Yang; Tongxin Sun
Journal:  Tumour Biol       Date:  2013-05-07

Review 2.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

3.  Thrombophilic polymorphisms are not associated with disease-free survival in breast cancer patients.

Authors:  Aydan Eroğlu; Ayfer Ezgi Yılmaz; Durdu Karasoy
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and tumor risk: evidence from 134 case-control studies.

Authors:  Min Tang; Shang-Qian Wang; Bian-Jiang Liu; Qiang Cao; Bing-Jie Li; Peng-Chao Li; Yong-Fei Li; Chao Qin; Wei Zhang
Journal:  Mol Biol Rep       Date:  2014-04-18       Impact factor: 2.316

5.  Risk of prostate cancer and thrombosis-related factor polymorphisms.

Authors:  Somayehsadat Ghasemi; Aydin Tavakoli; Mohamad Moghadam; Mohamad Ali Zargar; Maryam Abbaspour; Nasim Hatamnejadian; Ahmad Ebrahimi
Journal:  Biomed Rep       Date:  2013-10-04

6.  Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population.

Authors:  Nasser Attia Elhawary; Anmar Nassir; Hesham Saada; Anas Dannoun; Omar Qoqandi; Ammar Alsharif; Mohammed Taher Tayeb
Journal:  Dis Markers       Date:  2017-02-27       Impact factor: 3.434

7.  Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors' susceptibility.

Authors:  Shuaili Xu; Li Zuo
Journal:  Hereditas       Date:  2020-04-27       Impact factor: 3.271

8.  Bladder cancer: a simple model becomes complex.

Authors:  Giovanni Battista Di Pierro; Caterina Gulia; Cristiano Cristini; Giorgio Fraietta; Lorenzo Marini; Pietro Grande; Vincenzo Gentile; Roberto Piergentili
Journal:  Curr Genomics       Date:  2012-08       Impact factor: 2.236

Review 9.  Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer.

Authors:  Wei Xu; Haifeng Zhang; Fa Wang; Honghui Wang
Journal:  Diagn Pathol       Date:  2013-06-17       Impact factor: 2.644

10.  Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in psoriasis in southern Turkey.

Authors:  Muzeyyen Izmirli; Bilge Bulbul Sen; Eminenur Rifaioglu; Bulent Gogebakan; Ozgur Aldemir; Tuba Sen; Ozlem Ekiz; Davut Alptekin
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.